Citation:Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, et al 2011

From Cancer Guidelines Wiki

Citation


Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011 Jan 20;29(3):287-93 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21135284.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACPcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?